© 2004 European Society for Medical Oncology
Review |
Clinical trial design for microarray predictive marker discovery and assessment
Departments of 1 Breast Medical Oncology and 2 Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
* Correspondence to: Dr L. Pusztai, Department of Breast Medical Oncology, Unit 424, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA. Tel: +1-713-792-2817; Fax: +1-713-794-4385; Email: lpusztai{at}mdanderson.org
Transcriptional profiling technologies that simultaneously measure the expression of thousands of mRNA species represent a powerful new clinical research tool. Similar to previous laboratory analytical methods including immunohistochemistry, PCR and in situ hybridization, this new technology may also find its niche in routine diagnostics. Outcome predictors discovered by these methods may be quite different from previous single-gene markers. These novel tests will probably combine the information embedded in the expression of multiple genes with mathematical prediction algorithms to formulate classification rules and predict outcome. The performance of machine learning-algorithm-based diagnostic tests may improve as they are trained on larger and larger sets of samples, and several generations of tests with improving accuracy may be introduced sequentially. Several gene-expression profiling–technology platforms are mature enough for clinical testing. The most important next step that is needed for further progress is the development and validation of multigene predictors in prospectively designed clinical trials to determine the true accuracy and clinical value of this new technology. This manuscript reviews methodological and statistical issues relevant to clinical trial design to discover and validate multigene predictors of response to therapy.
Key words: clinical trials, microarrays, gene-expression profiling, predictive markers, multigene predictors
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. de Valpine, H.-M. Bitter, M. P. S. Brown, and J. Heller A simulation-approximation approach to sample size planning for high-dimensional classification studies Biostat., July 1, 2009; 10(3): 424 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Simon The Use of Genomics in Clinical Trial Design Clin. Cancer Res., October 1, 2008; 14(19): 5984 - 5993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. I. Dumur, M. Lyons-Weiler, C. Sciulli, C. T. Garrett, I. Schrijver, T. K. Holley, J. Rodriguez-Paris, J. R. Pollack, J. L. Zehnder, M. Price, et al. Interlaboratory Performance of a Microarray-Based Gene Expression Test to Determine Tissue of Origin in Poorly Differentiated and Undifferentiated Cancers J. Mol. Diagn., January 1, 2008; 10(1): 67 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Mehta, S. O. Zakharkin, G. L. Gadbury, and D. B. Allison Epistemological issues in omics and high-dimensional biology: give the people what they want Physiol Genomics, December 13, 2006; 28(1): 24 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Onken, L. A. Worley, R. M. Davila, D. H. Char, and J. W. Harbour Prognostic Testing in Uveal Melanoma by Transcriptomic Profiling of Fine Needle Biopsy Specimens J. Mol. Diagn., November 1, 2006; 8(5): 567 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Verducci, V. F. Melfi, S. Lin, Z. Wang, S. Roy, and C. K. Sen Microarray analysis of gene expression: considerations in data mining and statistical treatment Physiol Genomics, May 16, 2006; 25(3): 355 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Diskin, J. Kumar, Z. Cao, J. S. Schuman, T. Gilmartin, S. R. Head, and N. Panjwani Detection of differentially expressed glycogenes in trabecular meshwork of eyes with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1491 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Anderson, K. R. Hess, M. Kapoor, S. Tirrell, J. Courtemanche, B. Wang, Y. Wu, Y. Gong, G. N. Hortobagyi, W. F. Symmans, et al. Reproducibility of Gene Expression Signature-Based Predictions in Replicate Experiments Clin. Cancer Res., March 15, 2006; 12(6): 1721 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kerr Concordia res parvae crescent Ann. Onc., January 1, 2006; 17(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
|
|
C. H. Smorenburg, G. J. Peters, C. J. van Groeningen, P. Noordhuis, K. Smid, A. M. G. H. van Riel, W. Dercksen, H. M. Pinedo, and G. Giaccone Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase Ann. Onc., January 1, 2006; 17(1): 35 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Simon Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers J. Clin. Oncol., October 10, 2005; 23(29): 7332 - 7341. [Abstract] [Full Text] [PDF]
|
|